Big Pharma vet John Hohneker takes the reins at Anokion; Heptares co-founder Fiona Marshall resigns from parent company Sosei
→ Having worked in a slate of senior positions in pharma and biotech, John Hohneker is now taking the reins of Anokion as president and CEO. Most recently he was president of R&D at Forma Therapeutics, where he guided the company from discovery stage to clinical trials. In Hohneker, the Lausanne, Switzerland-headquartered biotech gets an experienced exec who’s spent a combined 20 years at GSK and Novartis. He’s been involved with the development, approval and commercialization of such drugs as Cosentyx, Gleevec, and Afinitor. His focus will be on developing the biotech’s immune tolerance platform for autoimmune disease, which has attracted Celgene to ink a collaboration deal with an option to buy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.